Sarah C Van Alsten
Overview
Explore the profile of Sarah C Van Alsten including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
120
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Van Alsten S, Love M, Calhoun B, Butler E, Perou C, Hoadley K, et al.
Cancer Res
. 2025 Jan;
PMID: 39879109
Cancer genomics consortia have identified somatic drivers of breast cancer subtypes. However, these studies have predominantly included older, non-Black women, and the related socioeconomic status (SES) data is limited. Increased...
2.
Van Alsten S, Zipple I, Calhoun B, Troester M
Cancer Causes Control
. 2024 Dec;
PMID: 39702817
The Surveillance Epidemiology and End Results (SEER) registry incorporates laterality, histology, latency, and topography to identify second primary breast cancers. Contralateral tumors are classified as second primaries, but ipsilaterals are...
3.
Dunn M, Li D, Emerson M, Thompson C, Nichols H, Van Alsten S, et al.
PLoS Med
. 2024 Dec;
21(12):e1004500.
PMID: 39621782
Background: Delays in breast cancer diagnosis and treatment lead to worse survival and quality of life. Racial disparities in care timeliness have been reported, but few studies have examined access...
4.
Van Alsten S, Vohra S, Ivory J, Hamilton A, Gao X, Kirk E, et al.
JCO Precis Oncol
. 2024 Jul;
8:e2400137.
PMID: 39013134
Purpose: Genomic tests, such as the Oncotype Dx 21-gene and Prosigna risk of recurrence (ROR-P) assay, are commonly used for breast cancer prognostication. Emerging data suggest variability between assays, but...
5.
Li Y, Van Alsten S, Lee D, Kim T, Calhoun B, Perou C, et al.
Cancers (Basel)
. 2024 Jul;
16(13).
PMID: 39001357
High intratumoral heterogeneity is thought to be a poor prognostic indicator. However, the source of heterogeneity may also be important, as genomic heterogeneity is not always reflected in histologic or...
6.
Hamilton A, Walens A, Van Alsten S, Olsson L, Nsonwu-Farley J, Gao X, et al.
Breast Cancer Res
. 2024 Mar;
26(1):50.
PMID: 38515208
Purpose: Survivin/BIRC5 is a proliferation marker that is associated with poor prognosis in breast cancer and an attractive therapeutic target. However, BIRC5 has not been well studied among racially diverse...
7.
Park J, Smith M, Van Alsten S, Walens A, Wu D, Hoadley K, et al.
Cancer Epidemiol Biomarkers Prev
. 2024 Mar;
33(5):721-730.
PMID: 38426904
Background: Somatic mutational signatures elucidate molecular vulnerabilities to therapy, and therefore detecting signatures and classifying tumors with respect to signatures has clinical value. However, identifying the etiology of the mutational...
8.
Van Alsten S, Dunn M, Hamilton A, Ivory J, Gao X, Kirk E, et al.
Cancer Epidemiol Biomarkers Prev
. 2024 Jan;
33(5):654-661.
PMID: 38270534
Background: OncotypeDx is a prognostic and predictive genomic assay used in early-stage hormone receptor-positive, HER2- (HR+/HER2-) breast cancer. It is used to inform adjuvant chemotherapy decisions, but not all eligible...
9.
Olsson L, Hamilton A, Van Alsten S, Lund J, Sturmer T, Nichols H, et al.
Breast Cancer Res Treat
. 2023 Dec;
204(1):107-116.
PMID: 38070094
Background: Breast cancer chemotherapy utilization not only may differ by race and age, but also varies by genomic risk, tumor characteristics, and patient characteristics. Studies in demographically diverse populations with...
10.
Hamilton A, Van Alsten S, Gao X, Nsonwu-Farley J, Calhoun B, Love M, et al.
Cancer Res Commun
. 2023 Mar;
3(1):12-20.
PMID: 36968228
Significance: Despite promising advances in breast cancer immunotherapy, predictive biomarkers that are valid across diverse populations and breast cancer subtypes are needed. Genomic instability signatures can be coordinated with other...